PAMIDRONATE DISODIUM
Clinical safety rating: avoid
Contraindicated (not allowed)
Bisphosphonate that inhibits osteoclast-mediated bone resorption by adsorbing to hydroxyapatite crystals and inhibiting their dissolution, and by inhibiting osteoclast activity via farnesyl pyrophosphate synthase inhibition.
| Metabolism | Not metabolized; excreted unchanged primarily by the kidneys. |
| Excretion | Primarily renal; 30-62% of unchanged drug excreted in urine within 72 hours, with the remainder bound to bone and slowly released. Biliary/fecal elimination is negligible (<1%). |
| Half-life | Triphasic: terminal elimination half-life (t1/2γ) is 27-28 hours, representing slow release from bone. Clinical context: prolonged suppression of bone resorption persists weeks after serum levels become undetectable. |
| Protein binding | Approximately 54%, mainly to albumin. |
| Volume of Distribution | 0.2-0.3 L/kg; distributes primarily to bone (particularly osteoclast-active surfaces) and liver, with minimal soft tissue penetration. |
| Bioavailability | Not applicable orally (negligible absorption, <1%). IV bioavailability is 100%. |
| Onset of Action | IV: Reduction in serum calcium begins within 24-48 hours, maximal effect at 4-7 days. No oral formulation. |
| Duration of Action | Serum calcium remains normalized for 2-3 weeks after a single IV dose; bone resorption inhibition may persist up to 6 months due to skeletal retention. |
| Molecular Weight | 369.14 |
90 mg intravenously over 2-24 hours every 3-4 weeks for hypercalcemia of malignancy; 60-90 mg intravenously over 2-24 hours every 2-4 weeks for osteolytic bone metastases or Paget disease.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if CrCl <30 mL/min. For CrCl 30-60 mL/min: reduce dose to 60 mg or extend infusion interval. Monitor serum creatinine prior to each dose. |
| Liver impairment | No specific dose adjustment recommended based on Child-Pugh score; use with caution in severe hepatic impairment. |
| Pediatric use | Not FDA-approved for pediatric use. Limited data: 0.5-2 mg/kg intravenously over 4-24 hours for hypercalcemia, but safety and efficacy not established. |
| Geriatric use | No specific dose adjustment based on age alone; assess renal function closely as elderly patients are more likely to have decreased creatinine clearance. Monitor for renal toxicity and electrolyte imbalances. |
| 1st trimester | Pamidronate disodium is contraindicated in pregnancy; animal studies show developmental toxicity, including skeletal abnormalities. Use only if clearly needed and no alternative. |
| 2nd trimester | Contraindicated; may cause fetal harm. Avoid use due to risk of hypocalcemia and skeletal effects. |
| 3rd trimester | Contraindicated; risk of neonatal hypocalcemia and persistent hypocalcemia. Use only if potential benefit justifies risk. |
Clinical note
Nephrotoxic drugs may increase risk of renal impairment Can cause renal impairment and hypocalcemia.
| Placental transfer | Pamidronate crosses the placenta; animal studies demonstrate skeletal alterations. Human data limited but suggests transfer. |
| Breastfeeding | Pamidronate is excreted in human milk in minimal amounts; however, due to potential for bone growth suppression and hypocalcemia in the infant, caution is advised. Consider alternative agents or temporarily discontinue breastfeeding. |
■ FDA Black Box Warning
Not indicated for osteoporosis. Risk of severe renal impairment, especially with rapid infusion. Osteonecrosis of the jaw has been reported.
| Common Effects | bone metastases |
| Serious Effects |
Hypersensitivity to pamidronate disodium or any bisphosphonateSevere renal impairment (creatinine clearance < 30 mL/min)HypocalcemiaPregnancyBreastfeeding (caution but not absolute)
| Precautions | Renal toxicity (monitor renal function, avoid in severe renal impairment), osteonecrosis of the jaw (dental exam before therapy), hypocalcemia (ensure adequate calcium/vitamin D), severe musculoskeletal pain, atrial fibrillation (in long-term use), bronchospasm in aspirin-sensitive asthmatics. |
| Food/Dietary | No specific dietary restrictions. However, ensure adequate calcium and vitamin D intake to prevent hypocalcemia, especially in patients receiving pamidronate for osteoporosis. Avoid concurrent high-calcium meals within 2 hours of oral bisphosphonates (not applicable to IV pamidronate). |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pamidronate disodium is pregnancy category D. First trimester: potential skeletal abnormalities, low birth weight. Second and third trimesters: risk of fetal hypocalcemia, skeletal dysplasia, reduced fetal growth. Animal studies show fetal skeletal delays and maternal toxicity. |
| Fetal Monitoring | Monitor maternal serum calcium, phosphate, magnesium, and renal function. Fetal ultrasound for skeletal assessment and growth monitoring. Assess for signs of hypocalcemia in mother and neonate post-delivery. |
| Fertility Effects | No human data; animal studies show impaired fertility at high doses due to altered calcium homeostasis. Potential for reversible ovarian dysfunction. |
| Clinical Pearls | Monitor serum calcium, phosphate, magnesium, and potassium closely; risk of renal toxicity requires assessment of renal function before each dose and dose reduction in creatinine clearance <30 mL/min. Ensure adequate hydration to prevent renal injury. First-dose hypocalcemia may occur; check calcium levels post-infusion. Avoid concomitant use with other nephrotoxic drugs. For hypercalcemia, rehydrate with normal saline before administration. |
| Patient Advice | Report any signs of hypocalcemia such as muscle cramps, numbness, or tingling around the mouth. · Drink plenty of water before and after infusion to protect kidneys. · Inform your doctor if you have kidney disease, are taking diuretics, or have dental problems. · You may experience bone pain, fever, or flu-like symptoms after infusion; these are usually temporary. · Regular dental check-ups are important due to risk of osteonecrosis of the jaw. |